Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1328Neoplasms 998Carcinoma, Non-Small-Cell Lung 865Prostatic Neoplasms 730Colorectal Neoplasms 671Lung Neoplasms 553Leukemia, Myeloid, Acute 475Neoplasm Metastasis 427Pancreatic Neoplasms 426Carcinoma, Hepatocellular 407Ovarian Neoplasms 393Multiple Myeloma 393Stomach Neoplasms 383Recurrence 369Squamous Cell Carcinoma of Head and Neck 327Melanoma 295Uterine Cervical Neoplasms 288Brain Neoplasms 288Triple Negative Breast Neoplasms 273Glioblastoma 263Head and Neck Neoplasms 260Precursor Cell Lymphoblastic Leukemia-Lymphoma 256Endometrial Neoplasms 238Lymphoma 230Esophageal Neoplasms 226Rectal Neoplasms 224Sarcoma 213Carcinoma, Renal Cell 205Colonic Neoplasms 196Lymphoma, Large B-Cell, Diffuse 194

Interventions

trilaciclib 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Interventional × Myelosuppression × Clear all
NCT06490081 2024-09-24

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
40 enrolled

Myelosuppression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡